Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
复制标题
替莫唑胺治疗顺铂难治性生殖细胞肿瘤患者的 II 期试验。
DOI：
10.1023/b:drug.0000011794.21608.59
复制
发表时间：
2004
影响因子：
3.4
通讯作者：
Motzer,RobertJ
中科院分区：
文献类型：
--
作者：
VaruniKondagunta,G;Bacik,Jennifer;Schwartz,Lawrence;Sheinfeld,Joel;Bajorin,Dean;Vuky,Jacqueline;Marion,Stephanie;Mazumdar,Madhu;Bosl,GeorgeJ;Motzer,RobertJ
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1–5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
